{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:53:22Z","timestamp":1778637202835,"version":"3.51.4"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2019-0508_s_999\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is a need for additional biomarkers to assist in the diagnosis and prognosis of rheumatoid arthritis (RA). The aim of our study was to evaluate the (pre-analytical, analytical and clinical) performance of serum calprotectin as a marker of inflammation in RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0508_s_998\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study population included 463 rheumatologic patients (including 111 RA patients and 352 controls) who for the first time consulted a rheumatologist, 20 healthy controls and 27 patients with an infectious disease. Calprotectin was measured (using four different assays) in serum or in serum and EDTA plasma (healthy controls and infectious disease group). For rheumatologic patients, results for C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) were available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0508_s_997\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Results for blood calprotectin were assay- and matrix-dependent, with higher values found in serum than in plasma. Serum calprotectin was higher in RA patients than in rheumatologic diseased controls and in healthy controls. Serum calprotectin was lower in RA patients than in patients with an infectious disease. Serum calprotectin was associated with disease activity (DAS score). The area under the curve (AUC) to discriminate RA from controls was 0.756 for CRP, 0.714 for ESR and 0.726\u20130.783 for calprotectin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2019-0508_s_996\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our data document that calprotectin measurement is assay- and matrix-dependent. Serum calprotectin is associated with disease activity. Additional (prospective) studies are warranted to further evaluate the prognostic and diagnostic value of blood calprotectin measurements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2019-0508","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T09:03:11Z","timestamp":1572426191000},"page":"40-49","source":"Crossref","is-referenced-by-count":25,"title":["Pre-analytical and analytical confounders of serum calprotectin as a biomarker in rheumatoid arthritis"],"prefix":"10.1515","volume":"58","author":[{"given":"Lieve","family":"Van Hoovels","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Onze-Lieve Vrouw Hospital , Moorselbaan 164 , 9300 Aalst , Belgium , Phone: +32 (0)53\/72 47 91"},{"name":"Department of Microbiology and Immunology , KU Leuven , Leuven , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Vander Cruyssen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology , Onze-Lieve Vrouw Hospital , Aalst , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bogaert","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Onze-Lieve Vrouw Hospital , Aalst , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Van den Bremt","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Onze-Lieve Vrouw Hospital , Aalst , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology , KU Leuven , Leuven , Belgium"},{"name":"Department of Laboratory Medicine , University Hospital Leuven , Leuven , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"2022031413395765902_j_cclm-2019-0508_ref_001","doi-asserted-by":"crossref","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023\u201338.","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_002","doi-asserted-by":"crossref","unstructured":"van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014;73:861\u201370.","DOI":"10.1136\/annrheumdis-2012-203130"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_003","doi-asserted-by":"crossref","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3\u201315.","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_004","doi-asserted-by":"crossref","unstructured":"Finckh A, Alpizar-Rodriguez D, Roux-Lombard P. Value of biomarkers in the prevention of rheumatoid arthritis. Clin Pharmacol Ther 2017;102:585\u20137.","DOI":"10.1002\/cpt.727"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_005","doi-asserted-by":"crossref","unstructured":"Takeuchi T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin Immunol 2018;186:59\u201362.","DOI":"10.1016\/j.clim.2017.07.019"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_006","doi-asserted-by":"crossref","unstructured":"Ometto F, Friso L, Astorri D, Botsios C, Raffeiner B, Punzi L, et al. Calprotectin in rheumatic diseases. Exp Biol Med 2017;242:859\u201373.","DOI":"10.1177\/1535370216681551"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_007","doi-asserted-by":"crossref","unstructured":"Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496\u2013502.","DOI":"10.1074\/jbc.272.14.9496"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_008","doi-asserted-by":"crossref","unstructured":"Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009;5:e1000639.","DOI":"10.1371\/journal.ppat.1000639"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_009","doi-asserted-by":"crossref","unstructured":"Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004;104:4260\u20138.","DOI":"10.1182\/blood-2004-02-0446"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_010","doi-asserted-by":"crossref","unstructured":"Kornd\u00f6rfer IP, Brueckner F, Skerra A. The crystal structure of the human (S100A8\/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins. J Mol Biol 2007;370:887\u201398.","DOI":"10.1016\/j.jmb.2007.04.065"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_011","doi-asserted-by":"crossref","unstructured":"Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042\u20139.","DOI":"10.1038\/nm1638"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_012","doi-asserted-by":"crossref","unstructured":"Baillet A, Trocm\u00e9 C, Berthier S, Arlotto M, Grange L, Chenau J, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology 2010;49:671\u201382.","DOI":"10.1093\/rheumatology\/kep452"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_013","doi-asserted-by":"crossref","unstructured":"Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol 2015;42:760\u201370.","DOI":"10.3899\/jrheum.140628"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_014","doi-asserted-by":"crossref","unstructured":"Bae SC, Lee YH. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Postgrad Med J 2017;129:531\u20137.","DOI":"10.1080\/00325481.2017.1319729"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_015","doi-asserted-by":"crossref","unstructured":"Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, et al. MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis 2015;74:499\u2013505.","DOI":"10.1136\/annrheumdis-2013-203923"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_016","doi-asserted-by":"crossref","unstructured":"Jonsson MK, Sundlis\u00e6ter NP, Nordal HH, Hammer HB, Aga AB, Olsen IC, et al. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Ann Rheum Dis 2017;76:2031\u20137.","DOI":"10.1136\/annrheumdis-2017-211695"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_017","doi-asserted-by":"crossref","unstructured":"Nordal HH, Brokstad KA, Solheim M, Halse AK, Kvien TK, Hammer HB. Calprotectin (S100A8\/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Arthritis Res Ther 2017;19:3.","DOI":"10.1186\/s13075-016-1201-0"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_018","doi-asserted-by":"crossref","unstructured":"Cerezo AL, Mann H, Pecha O, Ple\u0161tilov\u00e1 L, Pavelka K, Vencovsk\u00fd J, et al. Decreases in serum levels of S100A8\/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2011;13:R122.","DOI":"10.1186\/ar3426"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_019","doi-asserted-by":"crossref","unstructured":"Inciarte-Mundo J, Victoria Hern\u00e1ndez M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res 2016;68:899\u2013906.","DOI":"10.1002\/acr.22795"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_020","doi-asserted-by":"crossref","unstructured":"Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther 2011;13:R178.","DOI":"10.1186\/ar3503"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_021","doi-asserted-by":"crossref","unstructured":"Hammer HB, Odegard S, Fagerhol MK, Landew\u00e9 R, van der Heijde D, Uhlig T, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1093\u20137.","DOI":"10.1136\/ard.2006.064741"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_022","doi-asserted-by":"crossref","unstructured":"Hammer HB, \u00d8deg\u00e5rd S, Syversen SW, Landew\u00e9 R, van der Heijde D, Uhlig T, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:150\u20134.","DOI":"10.1136\/ard.2008.103739"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_023","doi-asserted-by":"crossref","unstructured":"Van Hoovels L, Jacobs J, Vander Cruyssen B, Van den Bremt S, Verschueren P, Bossuyt X. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR\/EULAR classification of rheumatoid arthritis. Ann Rheum Dis 2018;77:667\u201377.","DOI":"10.1136\/annrheumdis-2017-212365"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_024","doi-asserted-by":"crossref","unstructured":"Gong X, Xu SQ, Wu Y, Ma CC, Qi S, Liu W, et al. Elevated serum 14-3-3eta protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol 2017;36:2581\u20137.","DOI":"10.1007\/s10067-017-3807-2"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_025","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Evaluation of precision performance of quantitative measurement methods, approved guideline \u2013 second edition. Wayne, PA: CLSI, 2004. CLSI document. 2004; EP5-A2."},{"key":"2022031413395765902_j_cclm-2019-0508_ref_026","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Evaluation of the linearity of quantitative measurement procedures: a statistical approach, approved guideline. Wayne, PA: CLSI, 2003. CLSI document. 2003; EP6-A."},{"key":"2022031413395765902_j_cclm-2019-0508_ref_027","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Method comparison and bias estimation using patient samples, approved guideline \u2013 second edition. Wayne, PA: CLSI, 2013. CLSI document. 2013; EP9-A3."},{"key":"2022031413395765902_j_cclm-2019-0508_ref_028","doi-asserted-by":"crossref","unstructured":"Pedersen L, Birkemose E, Gils C, Safi S, Nybo M. Sample type and storage conditions affect calprotectin measurements in blood. JALM 2017. doi: 10.1373\/jalm.2017.024778.","DOI":"10.1373\/jalm.2017.024778"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_029","doi-asserted-by":"crossref","unstructured":"Nordal HH, Fagerhol MK, Halse AK, Hammer HB. Calprotectin (S100A8\/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis. Scan J Clin Lab Invest 2017;78:102\u20138.","DOI":"10.1080\/00365513.2017.1419371"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_030","doi-asserted-by":"crossref","unstructured":"Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo LA, Mann H, et al. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Clin Rheumatol 2018;37: 2055\u201362.","DOI":"10.1007\/s10067-018-4091-5"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_031","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arias M, Pascual-Salcedo D, Ramiro S, Ueberschlag ME, Jermann TM, Cara C, et al. Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther 2013;17:49\u201356.","DOI":"10.1007\/s40291-013-0016-9"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_032","doi-asserted-by":"crossref","unstructured":"Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol 2008;37:179\u201382.","DOI":"10.1080\/03009740701874451"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_033","doi-asserted-by":"crossref","unstructured":"Hurnakova J, Zavada J, Hanova P, Hulejova H, Klein M, Mann H, et al. Serum calprotectin (S100A8\/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. Arthritis Res Ther 2015;17:252.","DOI":"10.1186\/s13075-015-0764-5"},{"key":"2022031413395765902_j_cclm-2019-0508_ref_034","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569\u201381.","DOI":"10.1002\/art.27584"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2020.58.issue-1\/cclm-2019-0508\/cclm-2019-0508.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0508\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T14:36:36Z","timestamp":1647268596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2019-0508\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,14]]},"published-print":{"date-parts":[[2019,12,18]]}},"alternative-id":["10.1515\/cclm-2019-0508"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2019-0508","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,30]]}}}